BG99680A - Derivatives of oxalylaminobenzofuran and oxalylaminobenzothienyl - Google Patents

Derivatives of oxalylaminobenzofuran and oxalylaminobenzothienyl

Info

Publication number
BG99680A
BG99680A BG99680A BG9968095A BG99680A BG 99680 A BG99680 A BG 99680A BG 99680 A BG99680 A BG 99680A BG 9968095 A BG9968095 A BG 9968095A BG 99680 A BG99680 A BG 99680A
Authority
BG
Bulgaria
Prior art keywords
derivatives
oxalylaminobenzothienyl
oxalylaminobenzofuran
prophylaxy
aminosubstituted
Prior art date
Application number
BG99680A
Other languages
English (en)
Inventor
Gabriele Braeunlich
Ruediger Fischer
Mazen Es-Sayed
Rudolf Hanko
Stephen Tudhope
Graham Sturton
Trevor Abram
Wendy J Donald-Gibson
Mary F Fitzgerald
Original Assignee
Braeunlich
Fischer
Es Sayed
Hanko
Tudhope
Sturton
Abram
Donald Gibson
Fitzgerald
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9410891A external-priority patent/GB9410891D0/en
Priority claimed from GB9410863A external-priority patent/GB9410863D0/en
Application filed by Braeunlich, Fischer, Es Sayed, Hanko, Tudhope, Sturton, Abram, Donald Gibson, Fitzgerald filed Critical Braeunlich
Publication of BG99680A publication Critical patent/BG99680A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Materials For Photolithography (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Optical Record Carriers (AREA)
BG99680A 1994-05-31 1995-05-30 Derivatives of oxalylaminobenzofuran and oxalylaminobenzothienyl BG99680A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9410891A GB9410891D0 (en) 1994-05-31 1994-05-31 Oxalylamino-benzofuran-and benzothienyl-derivatives
GB9410863A GB9410863D0 (en) 1994-05-31 1994-05-31 Heterocyclycarbonyl substituted oxalylamino-benzofurane derivatives

Publications (1)

Publication Number Publication Date
BG99680A true BG99680A (en) 1996-01-31

Family

ID=26304969

Family Applications (1)

Application Number Title Priority Date Filing Date
BG99680A BG99680A (en) 1994-05-31 1995-05-30 Derivatives of oxalylaminobenzofuran and oxalylaminobenzothienyl

Country Status (29)

Country Link
US (1) US5565488A (fr)
EP (1) EP0685474B1 (fr)
JP (1) JPH083154A (fr)
KR (1) KR950032163A (fr)
CN (1) CN1119187A (fr)
AT (1) ATE171172T1 (fr)
AU (1) AU695464B2 (fr)
BG (1) BG99680A (fr)
CA (1) CA2150301A1 (fr)
CO (1) CO4600675A1 (fr)
CZ (1) CZ140895A3 (fr)
DE (1) DE69504753T2 (fr)
DK (1) DK0685474T3 (fr)
EE (1) EE9500034A (fr)
ES (1) ES2124461T3 (fr)
FI (1) FI952612A (fr)
HR (1) HRP950288A2 (fr)
HU (1) HUT71597A (fr)
IL (1) IL113894A (fr)
LV (1) LV11467B (fr)
MA (1) MA23603A1 (fr)
MY (1) MY130580A (fr)
NO (1) NO952129L (fr)
NZ (1) NZ272217A (fr)
PL (1) PL308825A1 (fr)
RO (1) RO113642B1 (fr)
SK (1) SK72195A3 (fr)
TN (1) TNSN95061A1 (fr)
ZA (1) ZA954400B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
GB9614718D0 (en) * 1996-07-12 1996-09-04 Bayer Ag 3-ureido-pyridofurans and -pyridothiophenes
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
IL147688A0 (en) 1999-08-21 2002-08-14 Byk Gulden Lomberg Chem Fab Synergistic combination
US7144885B2 (en) 2002-02-22 2006-12-05 Bayer Pharmaceuticals Corporation Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
EP1478639A1 (fr) * 2002-02-22 2004-11-24 Bayer Pharmaceuticals Corporation Heterocycles tricycliques fusionnes utilises dans le traitement de troubles hyperproliferatifs
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR20050115331A (ko) 2003-04-01 2005-12-07 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 불임증 포스포디에스터라제의 억제제
JP2006526608A (ja) * 2003-06-05 2006-11-24 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー Ｐｉ３ｋ活性を有する治療薬としてのテトラゾールベンゾフランカルボキシアミド
ATE365735T1 (de) * 2003-06-05 2007-07-15 Warner Lambert Co Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel
WO2004108708A1 (fr) * 2003-06-05 2004-12-16 Warner-Lambert Company Llc Indoles 3-substitues et leurs derives utilises comme agents therapeutiques
MXPA05013061A (es) * 2003-06-05 2006-03-02 Warner Lambert Co Benzotiofenos sustituidos con cicloalquilos y heterocicloalquilos como agentes terapeuticos.
MXPA05012953A (es) * 2003-06-05 2006-02-13 Warner Lambert Co Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
US20040259926A1 (en) * 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
CA2537119A1 (fr) * 2003-09-02 2005-03-10 Merck & Co., Inc. Compositions ophtalmiques pour le traitement de l'hypertension oculaire
CA2666469A1 (fr) * 2006-09-01 2008-03-06 Bayer Healthcare Ag Derives de benzofurane et de benzothiophene utiles dans le traitement de cancers du systeme nerveux central
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (fr) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (fr) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
IN2012DN00720A (fr) 2009-07-06 2015-06-19 Ontorii Inc
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
EA201391254A1 (ru) 2011-03-01 2014-02-28 Синерджи Фармасьютикалз Инк. Способ получения агонистов гуанилатциклазы c
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 官能化核酸の合成のための方法
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
CA2902348C (fr) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et applications associees
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
WO2014151206A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
WO2014197720A2 (fr) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation
US20160184387A1 (en) 2013-08-09 2016-06-30 Dominique Charmot Compounds and methods for inhibiting phosphate transport
KR20220106232A (ko) 2014-01-16 2022-07-28 웨이브 라이프 사이언시스 리미티드 키랄 디자인
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146243A1 (fr) 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Inhibiteurs de la lipoxygénase
US5120742A (en) * 1984-02-27 1992-06-09 Merck & Co., Inc. 17 β-acyl-4-aza-5 α-androst-1-ene-3-ones as 5 α-reductase inhibitors
GB9200623D0 (en) * 1992-01-13 1992-03-11 Bayer Ag Benzofuranyl and thiophenyl-methylthio-alkanecarboxylic acid derivatives
GB9309324D0 (en) * 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives

Also Published As

Publication number Publication date
PL308825A1 (en) 1995-12-11
AU695464B2 (en) 1998-08-13
KR950032163A (ko) 1995-12-20
NO952129D0 (no) 1995-05-30
EP0685474B1 (fr) 1998-09-16
EE9500034A (et) 1995-12-15
ES2124461T3 (es) 1999-02-01
DE69504753T2 (de) 1999-02-04
ATE171172T1 (de) 1998-10-15
HU9501569D0 (en) 1995-07-28
FI952612A0 (fi) 1995-05-29
AU2028695A (en) 1995-12-07
HUT71597A (en) 1996-01-29
IL113894A0 (en) 1995-08-31
CO4600675A1 (es) 1998-05-08
LV11467A (lv) 1996-08-20
EP0685474A1 (fr) 1995-12-06
SK72195A3 (en) 1995-12-06
FI952612A (fi) 1995-12-01
CZ140895A3 (en) 1995-12-13
NZ272217A (en) 1997-02-24
CN1119187A (zh) 1996-03-27
ZA954400B (en) 1996-01-24
JPH083154A (ja) 1996-01-09
CA2150301A1 (fr) 1995-12-01
MA23603A1 (fr) 1996-04-01
TNSN95061A1 (fr) 1996-02-06
IL113894A (en) 1999-06-20
RO113642B1 (ro) 1998-09-30
HRP950288A2 (en) 1997-08-31
DE69504753D1 (de) 1998-10-22
NO952129L (no) 1995-12-01
MY130580A (en) 2007-06-29
DK0685474T3 (da) 1999-06-14
US5565488A (en) 1996-10-15
LV11467B (en) 1996-12-20

Similar Documents

Publication Publication Date Title
BG99680A (en) Derivatives of oxalylaminobenzofuran and oxalylaminobenzothienyl
DE3868076D1 (de) Heterocyclische derivate, verfahren zu ihrer herstellung und diese derivate als aktive bestandteile enthaltende fungizide.
HK1031869A1 (en) 1-Ä(1-Substituted-4-piperidinyl)methylÜ-4-piperdine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds.
DE3677478D1 (de) N-benzoylharnstoffverbindungen, diese enthaltende antitumorzusammensetzungen und verfahren zu deren herstellung.
DE69019180T2 (de) Organopolysiloxan-Polyharnstoff Blockcopolymer und Methode zu seiner Herstellung.
DE3576500D1 (de) Carbostyrilverbindungen, diese enthaltende zubereitungen und verfahren zu ihrer herstellung.
DE590131T1 (de) Neues endbehandlungsverfahren für hydroxyfunktionelle polythethern.
DE58905246D1 (de) Heterocyclische substituierte alkoxycumarine, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
MY117381A (en) Use of 1-hydroxy-2-pyridone for the treatment of seborrheic dermatitis
ATE9160T1 (de) Thienopyridinonderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung.
YU13499A (sh) Primena 1-hidroksi-2-piridona za lečenje seboroitičnog dermatitisa
FR2691078B1 (fr) Catalyseur d'hydrodesulfuration, procedes pour sa preparation et procede d'hydrodesulfuration l'utilisant.
GB2287953B (en) High stability, organic tanning processes
DE3880953D1 (de) Chinolinderivate, verfahren zur herstellung davon und diese enthaltendes antibakterielles mittel.
EP0668264A3 (fr) Composés d'or organiques soufrés, procédé pour leur préparation et leur utilisation.
ES2138215T3 (es) Metodo para eliminar un color no deseado de acido clorhidrico.
EP0663234A3 (fr) Procédé pour la décontamination aérobic microbiologique de gaz.
ITMI911877A1 (it) Enzimi fibrinolitici ammidati e loro precursori, e processi per la loro preparazione.
EP0679655A3 (fr) Procédé de préparation de dérivés d'acide ascorbique.
EP0682118A3 (fr) Procédé pour purifier des inulooligosaccharides cycliques.
HK1017332A1 (en) Method for preparing ferric polysulfate solutions.
ZA82347B (en) New organic compounds,processes for their production and their use
ZA824647B (en) New organic compounds,processes for their production and their use
EP0572030A3 (fr) Procédé de purification du 4,4' Diaminodiphénylméthane.
AU7952498A (en) Low-alloy cast iron tappet, apparatus, and process for its manufacturing